This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
AMY2A / Pancreatic alpha-amylase · IHC design guide
Design Immunohistochemistry for AMY2A
Plan paraffin section IHC for AMY2A using pancreatic exocrine cells as the expected positive population (HPA tissue IHC). This guide covers fixation, detection and interpretation of the observed cytoplasmic pattern (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
AMY2A Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic staining in pancreatic exocrine cells (HPA tissue IHC) | |
| Staining pattern | Selective cytoplasmic staining in pancreatic exocrine cells (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen) | |
| Positive control | Pancreas | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across paraffin sections. (standard IHC practice; not target-specific) | |
| Caveat | Staining may include protein from another gene (HPA tissue IHC) | |
| Regulation | Expression regulation is not annotated (UniProt) | |
| Isoform / epitope | 2 isoforms; signal peptide 1–15 is removed; epitope impact unknown (UniProt) |
Section 1
Recommended AMY2A IHC & IF Protocols
Compare the catalog antibody’s IHC-P protocol with a published AMY2A brain-section IHC workflow (PMC8028266).
| Sample | Paraffin-embedded human liver injury tissue; fixative not specified (datasheet A06771) |
| Fixation | Image fixative and duration unreported (datasheet A06771); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in citrate buffer, pH 6.0, 20 min at 95–98 °C (standard rule: cytoplasmic / membrane antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-AMY2A, 1:50-1:200 (datasheet A06771) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | AMY2A-positive staining in exocrine glandular cells of pancreas (HPA tissue IHC: High). HPA tissue profile: Selective cytoplasmic expression in pancreatic exocrine glandular cells. No signal in the no-primary control. |
💡Decision noteStart with citrate pH 6.0 retrieval at 95–98 °C for 20 min (page retrieval rule); the published workflow does not specify retrieval (PMC8028266).
Section 2
What Is the Expected AMY2A Staining Pattern?
In paraffin-section IHC, expect selective, strong cytoplasmic staining in pancreatic exocrine glandular cells (HPA: High; Enhanced tissue reliability). AMY2A is a secreted protein without a transmembrane segment, so its biology also permits protein outside cells (UniProt P04746: secreted; no transmembrane segment). HPA cautions that its antibodies can target proteins from more than one gene; this pattern alone does not establish AMY2A-specific staining (HPA: tissue IHC caution).
| Strong cytoplasmic staining in pancreatic exocrine glandular cells, with little signal elsewhere. | This matches the reported selective tissue pattern (HPA: High in pancreatic exocrine glandular cells; Enhanced tissue reliability). Record intensity and the fraction of stained cells together, since a strong signal in a few cells differs from widespread exocrine staining (general IHC practice). |
| Predominantly nuclear or sharply cell-membrane staining, with little exocrine cytoplasmic signal. | This does not match the reported IHC pattern (HPA: selective cytoplasmic expression). A membrane-only pattern also lacks support from the recorded topology (UniProt P04746: no transmembrane segment). Check morphology and detection artefacts before interpreting it as AMY2A localisation (general IHC practice). |
| Strong staining in adipocytes or other cells outside the expected pancreatic exocrine population. | Adipocytes are reported as not detected in adipose tissue (HPA: Not detected in adipocytes). Consider antibody recognition of another protein, including another gene product, or endogenous detection activity; morphology alone cannot identify the cause (HPA: multi-gene targeting caution; general IHC practice). |
| Diffuse colour across tissue, empty spaces, or section edges, without a clear cellular pattern. | The distribution is difficult to score against the selective exocrine cytoplasmic reference (HPA: tissue IHC profile). Because AMY2A is secreted, extracellular signal is biologically possible, but a diffuse deposit alone cannot establish target-specific staining (UniProt P04746: secreted; general IHC practice). |
| No staining in pancreatic exocrine glandular cells on the positive-control section. | This conflicts with the reported high signal in those cells (HPA: High in pancreatic exocrine glandular cells). Review tissue identity, section integrity, antibody and detection steps before calling the test specimen negative (general IHC practice). |
💡Expected AMY2A appearanceCall a section consistent with the reference pattern when pancreatic exocrine glandular cells show strong cytoplasmic staining (HPA: High; selective cytoplasmic expression); isolated nuclear staining or strong adipocyte staining is a warning pattern (HPA: tissue IHC profile; Not detected in adipocytes).
| Secretory route and processing | AMY2A has a signal peptide at residues 1–15 and a mature chain at 16–511; it is secreted (UniProt P04746: processing; subcellular location). These facts support caution when judging extracellular colour, but do not establish a specific luminal staining pattern in paraffin sections. |
| Antibody specificity and validation | HPA rates the tissue pattern Enhanced, while warning that antibodies can target products of multiple genes (HPA: tissue reliability and caution). Individual listed IHC ratings differ: CAB045960 is Enhanced; HPA045394, HPA045399 and HPA046980 are Supported (HPA: antibody validation). Match any conclusion to the antibody used. |
| IF/ICC Q: What localisation should be expected? | HPA reports Golgi apparatus localisation as approved and cytosol as uncertain in ICC-IF (HPA: subcellular profile). That evidence comes with a multi-gene antibody caution and does not replace the pancreatic exocrine cytoplasmic IHC reference (HPA: subcellular caution; tissue IHC profile). |
| Isoforms and modifications | UniProt lists two isoforms and one glycosylation site at residue 476 (UniProt P04746: isoforms; glycosylation). The supplied record gives no antibody epitope or isoform-specific staining result, so these annotations cannot explain a positive or negative section on their own. |
| Situation | Likely cause | Next action |
|---|---|---|
| Pancreatic positive control is blank. | An interrupted IHC workflow or unsuitable control section is possible; the expected exocrine signal is High (HPA: tissue IHC profile; general IHC practice). | Confirm exocrine morphology, then check primary-antibody application, detection reagents and chromogen with a working control (general IHC practice). Do not assign a target-specific fixation effect from this result. |
| Exocrine cells stain weakly despite a readable section. | The observed signal falls below the reported High reference pattern, but the stain alone does not identify which workflow step limited detection (HPA: tissue IHC profile; general IHC practice). | Check the antibody's IHC validation and compare positive-control sections processed alongside the test; adjust routine retrieval or detection conditions only with appropriate controls (HPA: antibody validation; general IHC practice). |
| Nuclei dominate the colour pattern. | Nuclear predominance is inconsistent with the reported selective cytoplasmic IHC pattern (HPA: tissue IHC profile). | Check the counterstain and chromogen distribution, then review a positive control for cytoplasmic staining before scoring the section (general IHC practice). |
| Adipocytes or broadly unrelated cells stain strongly. | Adipocytes are reported as not detected; multi-gene antibody recognition or nonspecific detection remains possible (HPA: adipose tissue; multi-gene caution; general IHC practice). | Compare with a no-primary control and the pancreatic positive control, and interpret any residual signal at the cell-type level (general IHC practice; HPA: High in pancreatic exocrine cells). |
| Colour spreads across tissue or pools outside cells. | Secreted protein may occur extracellularly, while diffuse chromogen or nonspecific background can look similar (UniProt P04746: secreted; general IHC practice). | Inspect tissue boundaries and cellular detail; compare a no-primary control before attributing diffuse signal to AMY2A (general IHC practice; HPA: multi-gene caution). |
| Two antibodies give different tissue patterns. | HPA lists different per-antibody IHC validation levels and cautions about multi-gene targeting (HPA: antibody validation; tissue IHC caution). | Record which antibody produced each pattern, compare each against the pancreatic exocrine reference, and avoid treating agreement with one antibody as proof of AMY2A specificity (HPA: tissue IHC profile and caution). |
Experiment evidence
IHC & IF images showing AMY2A staining
A06771 · IHCImmunohistochemistry of paraffin-embedded human liver injury using AMY2A antibody at dilution of 1:100 (x40 lens).
A06771 · IHCImmunohistochemistry of paraffin-embedded human gastric cancer using AMY2A antibody at dilution of 1:100 (x40 lens).
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000243480-AMY2A/tissue/cerebral+cortex#imid_14688580
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000243480-AMY2A/tissue/colon#imid_14681786
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000243480-AMY2A/tissue/liver#imid_14681795
HPA · PancreasHuman Protein Atlas IHC, Pancreas. Source: https://www.proteinatlas.org/ENSG00000243480-AMY2A/tissue/pancreas#imid_14682314
HPA · ICC-IF EFO-21Human Protein Atlas immunofluorescence, EFO-21, antibody HPA045394; green = AMY2A, blue = nucleus, red = microtubules.
HPA · ICC-IF EFO-21Human Protein Atlas immunofluorescence, EFO-21, antibody HPA045394; green = AMY2A, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for AMY2A IHC & IF
🧪Run pancreas first: exocrine glandular cells should stain strongly (HPA: High in pancreatic exocrine glandular cells). Use adipose tissue as a negative comparator (HPA: Not detected in adipocytes); non-exocrine cells on the pancreas slide should show only background staining and serve as an internal background reference.
Positive control tissue: Pancreas (Exocrine glandular cells, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show AMY2A in EFO-21, SiHa, U2OS, with annotated localisation: Golgi apparatus (approved), Cytosol (uncertain) (HPA subcellular).
Technical controls: Include a no-primary (secondary-only) control, an isotype control matched to the primary antibody’s host species and clonality, and an AMY2A knockout or immunizing-peptide block control where available (standard IHC practice). Quench endogenous peroxidase for chromogenic detection and assess endogenous biotin if using avidin–biotin detection (standard IHC practice).
⚠️Feasibility: A target-specific fixation window, fixation effect, and antigen-retrieval dependency are unreported in the supplied evidence; the paraffin-section caption for A06771 reports 1:100 but does not state a fixative (caption: A06771). The evidence does not establish whether frozen sections or IF/ICC are easier; the HPA ICC-IF localization carries a caution about antibodies targeting proteins from multiple genes (HPA subcellular). Because AMY2A is secreted, assess possible luminal or extracellular staining separately from exocrine-cell staining (UniProt P04746: secreted, extracellular space).
HPA tissue IHC evidence for AMY2A
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — High consistency between antibody staining and RNA expression data. Caution, targets protein from more than one gene. Secreted protein, tissue location of RNA and protein is expected to differ.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Pancreas | Exocrine glandular cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Appendix | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Breast | Adipocytes | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced AMY2A IHC Tips
Use pancreatic exocrine staining as the main reference while checking compartment, tissue integrity, and controls before interpreting AMY2A chromogenic IHC (HPA tissue IHC).
How should I retrieve AMY2A in paraffin sections when pancreatic staining is weak?
Use citrate buffer at pH 6.0 for heat induced retrieval at 95–98 °C for 20 min (page retrieval setting). Run a pancreatic section alongside the study sections, then compare exocrine cytoplasmic staining and tissue preservation before changing retrieval conditions (HPA tissue IHC; standard IHC practice). If staining remains weak, test a longer retrieval time on adjacent sections while holding antibody dilution and detection constant, and reject conditions that damage morphology (standard IHC practice). Because the selected product caption reports paraffin embedded liver injury at 1:100 without a fixative or retrieval method, that image cannot establish an optimal retrieval condition (A06771 caption).
Could fixation explain weak or uneven AMY2A staining?
Target specific fixation sensitivity is unknown: the selected paraffin section caption does not state a fixative, and the supplied record provides no fixation comparison (A06771 caption; UniProt P04746 record). Record the actual fixative and fixation interval for each specimen, then compare sections processed together before attributing a weak result to fixation (standard IHC practice). Use a pancreatic exocrine reference section and inspect morphology, because loss of architecture can make staining difficult to score reliably (HPA tissue IHC; standard IHC practice). Keep retrieval at citrate pH 6.0, 95–98 °C for 20 min during this comparison so fixation remains the variable under review (page retrieval setting).
Which staining compartment should count as AMY2A positive?
Score convincing cytoplasmic staining in pancreatic exocrine glandular cells as the principal tissue pattern (HPA tissue IHC). AMY2A has a signal peptide at residues 1–15, a mature chain at 16–511, no transmembrane segment, and a secreted extracellular destination (UniProt P04746 record). Secreted material can appear beyond its producing cell, so annotate extracellular signal separately from cellular staining and avoid assigning production from deposited protein alone (UniProt P04746 record; standard IHC interpretation). Golgi staining is reported in cell imaging, but that report cautions that its antibodies target proteins from multiple genes; use it as context rather than proof of AMY2A specificity (HPA subcellular).
Can this stain distinguish AMY2A isoforms or related amylases?
Do not label either of the 2 reported AMY2A isoforms separately unless the antibody epitope and isoform coverage have been established (UniProt P04746 record; standard IHC interpretation). The supplied evidence gives no epitope sequence, and the tissue atlas cautions that its antibody staining can represent proteins from more than one gene (HPA tissue IHC). AMY2A processing removes signal residues 1–15, while a glycosylation site at 476 and modified residue at 16 are annotated; these features make epitope location relevant to antibody interpretation (UniProt P04746 record). Compare any discordant antibodies on matched sections and report each reagent's staining pattern without claiming isoform specificity from chromogenic signal alone (standard IHC practice).
How can IF help check the cell source and compartment of AMY2A signal?
For a separate IF experiment, pair the AMY2A channel with an independently validated pancreatic exocrine cell marker and assess cellular overlap on the same section (HPA tissue IHC; standard IF practice). Choose a fluorophore in a channel with low measured tissue autofluorescence, and include an unstained section to identify autofluorescent structures before interpreting overlap (standard IF practice). If the antibody epitope is intracellular, use controlled permeabilisation; if the epitope is exposed extracellularly, compare staining without permeabilisation to preserve compartment information (UniProt P04746 topology; standard IF practice). Interpret apparent Golgi or cytosolic signal cautiously because the supplied cell imaging localisation used antibodies that can target proteins from multiple genes (HPA subcellular).
What should I check when the DAB background obscures exocrine staining?
First inspect a section processed without primary antibody to locate signal from the detection system, and review wash quality and reagent coverage on the affected slide (standard chromogenic IHC practice). Include a peroxidase block before DAB detection and check whether diffuse colour persists in the no primary control (standard chromogenic IHC practice). Compare background with pancreatic exocrine staining on a reference section, because that selective cytoplasmic pattern is the supplied tissue benchmark (HPA tissue IHC). If widespread colour follows tissue folds, damaged edges, or necrotic areas, exclude those regions from scoring and reassess antibody concentration on intact adjacent sections (standard IHC practice).
How should I quantify AMY2A across pancreatic IHC sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define pancreatic exocrine glandular cells as the scoring population and outline comparable viable regions before reviewing treatment labels (HPA tissue IHC; standard IHC practice). Report the percentage of positive exocrine cells and an H-score using intensity grades 0–3, or report positive area per mm² when cell boundaries are unreliable (standard IHC scoring practice). Normalise each result to the number or area of viable exocrine cells examined, and record excluded ducts, folds, necrosis, and tissue edges (standard IHC practice). Keep exposure, DAB development, counterstain, and the positivity threshold consistent across sections; report extracellular signal separately because AMY2A is secreted (UniProt P04746 record; standard IHC practice).
When is an apparent AMY2A positive cell likely to be artefact?
Give greatest weight to reproducible cytoplasmic staining in viable pancreatic exocrine glandular cells, the supplied high expression pattern (HPA tissue IHC). Question isolated nuclear staining or a sharp rim restricted to a section edge, and compare those areas with intact interior tissue and a no primary control (UniProt P04746 topology; standard IHC practice). Exclude necrotic areas and investigate DAB colour that persists without primary antibody, since endogenous enzyme activity or detection background can mimic a positive reaction (standard chromogenic IHC practice). Because AMY2A is secreted and the atlas warns that its antibodies can detect proteins from multiple genes, extracellular deposits or unexpected cell staining alone do not establish AMY2A expression by that cell (UniProt P04746 record; HPA tissue IHC).
Boster reagents
Best AMY2A / Pancreatic alpha-amylase IHC Antibodies
A06771 has IHC images from paraffin-embedded human liver injury and gastric cancer samples (IHC image captions). The catalog lists human, mouse and rat reactivity; it provides no IF data (catalog: reactivity and applications).
Real IHC data
Anti-Pancreatic alpha-amylase AMY2A Antibody
Cat # A06771
A06771 will render with an IHC figure from paraffin-embedded human liver injury at 1:100 (IHC image caption). A second caption shows paraffin-embedded human gastric cancer at 1:100; the catalog lists IHC and human, mouse and rat reactivity (IHC image caption; catalog: applications and reactivity).
Which to pick: Choose A06771 for paraffin-section IHC: its caption shows that processing, while the fixative is unreported (IHC image caption). A06771 has no listed IF/ICC application or IF figure, so there is no supported IF/ICC pick here (catalog: applications and IF image alts). For mouse or rat work, A06771 lists reactivity in both species, but its IHC captions show human samples only; clonality is unspecified (catalog: reactivity and clone; IHC image captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P04746 (AMYP_HUMAN, Pancreatic alpha-amylase).
- Human Protein Atlas. AMY2A tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. AMY2A subcellular location (ICC-IF): Localized to the Golgi apparatus and cytosol. Caution: Based on antibodies targeting proteins from multiple genes..
- Human Protein Atlas. AMY2A antibody validation summary (4 antibodies).
- Brain alpha-amylase: a novel energy regulator important in Alzheimer disease?. Brain pathology (Zurich, Switzerland) 2018 — PMC8028266.
- PubMed PMID:6610603 — UniProt-cited evidence.
- PubMed PMID:2450054 — UniProt-cited evidence.
- PubMed PMID:6336237 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for AMY2A (Pancreatic alpha-amylase). Expected localisation Cytoplasmic staining in pancreatic exocrine cells (HPA tissue IHC). Antigen retrieval: Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen). Validated IHC antibody: A06771 at 1:50-1:200 (the product's own IHC validation image is shown). Controls (HPA): positive Pancreas (Exocrine glandular cells); negative Adipose tissue. IHC workflow; specimen preparation unspecified. Protocol steps: 1. Sample: Paraffin-embedded human liver injury tissue; fixative not specified (datasheet A06771); 2. Fixation: Image fixative and duration unreported (datasheet A06771); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in citrate buffer, pH 6.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-AMY2A, 1:50-1:200 (datasheet A06771); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep fixation consistent across paraffin sections. (standard IHC practice; not target-specific); Caveat: Staining may include protein from another gene (HPA tissue IHC); Isoform / epitope: 2 isoforms; signal peptide 1–15 is removed; epitope impact unknown (UniProt); Regulation: Expression regulation is not annotated (UniProt). Evidence: UniProt P04746, HPA tissue IHC · Enhanced, HPA ICC-IF · Golgi apparatus and cytosol. Caution: Based on antibodies targeting…, Datasheet A06771, PMC8028266. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/AMY2A/immunohistochemistry-ihc-guide.